Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of ...

Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.

NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported financial results for the year ended December 31, 2025, and said it expects pivotal Phase 3 data for its lung ...

Strengthened Executive Leadership. In February 2026, Foghorn appointed Ryan Maynard as Chief Financial Officer. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...

The Fc fusion protein market thrives on innovative therapies targeting oncological and genetic disorders. Key opportunities lie in developing stable and soluble treatments, partnering with research ...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b ...

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported ...